DUBLIN--(BUSINESS WIRE)--The "Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...
Neonatal Respiratory Distress Syndrome (NRDS) remains a pressing concern in neonatal care, being a leading cause of morbidity among newborn infants. Its aetiology is frequently linked to surfactant ...
Bringing the newborn home is such a special and emotional experience for parents, and yet with it come some unexpected challenges. One concern is Newborn Respiratory Distress Syndrome, wherein the ...
Pregnant woman holding her stomach Maternal TSH levels >4 mIU/L are associated with increased risks for prematurity and neonatal respiratory distress syndrome. In pregnant women, maternal thyrotropin ...
Please provide your email address to receive an email when new articles are posted on . Minimally invasive surfactant therapy did not lower mortality among preterm infants with respiratory distress ...
LA JOLLA, CA - Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin® (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant ...
Scientists at the University of Southampton's Zepler Institute for Photonics and Nanoelectronics are developing a rapid bedside test for diagnosing neonatal Respiratory Distress Syndrome (nRDS) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results